IPO Calendar
Upcoming IPOs with underwriters, number of shares, offering price, and timing of the offering. See times when analysts are allowed to rate stocks and when company employees can not sell their stocks after an IPO.
Updated: 04-Nov-26 09:09 ET
Ends: 03-Nov-26 | Co: TRXB
TRex Bio, Inc. (Nasdaq) | Clinical-stage biopharmaceutical company focused on tissue Treg biology for discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair | Opened: 09-Oct-26, $13.50 | Priced: $14.00 | Underwriters: Lead: J.P.Morgan, Cantor/Evercore ISI, Stifel/, Wedbush PacGrow |
Ends: 09-Nov-26 | Co: IAM
Iambic Therapeutics (Nasdaq) | Phase 1 clinical biotech that uses its AI platform to design small molecule cancer drugs | Opened: 15-Oct-26, $16.15 | Priced: $16.00 | Underwriters: Lead: J.P.Morgan, Jefferies, BofA Securities, Citigroup |
Ends: 17-Nov-26 | Co: LYCA
Lycia Therapeutics (Nasdaq) | Clinical-stage biotechnology focused on discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with initial focus on addressing autoimmune, inflammatory and allergic diseases | Opened: 23-Oct-26, $28.55 | Priced: $18.00 | Underwriters: Lead: Jefferies, TD Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital |
Ends: 24-Nov-26 | Co: ASPE
Aspen Neuroscience (Nasdaq) | Clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies | Opened: 30-Oct-26, $14.70 | Priced: $15.00 | Underwriters: Lead: Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, Oppenheimer & Co. |
Ends: 24-Nov-26 | Co: BBTX
Bambusa Therapeutics (Nasdaq) | Clinical biotech developing next-generation and long-acting precision bispecific therapies for autoimmune and inflammatory diseases | Opened: 30-Oct-26, $14.88 | Priced: $16.00 | Underwriters: Lead: BofA Securities, Evercore ISI, UBS Investment Bank, Cantor |
